The EMA grants Orphan Medicinal Product status to Verastem's (VSTM) small molecule inhibitor...


The EMA grants Orphan Medicinal Product status to Verastem's (VSTM) small molecule inhibitor VS-6063 for the treatment of mesothelioma. The designation gives the drug a leg up in terms of market exclusivity upon approval and opens the door for EMA assistance throughout clinical development. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs